Prof. dr hab. n. med. Mirosław Markiewicz

Publikacje

• [współaut.] Kopacz A, Blajer-Olszewska B, Mazur M [et al.] Rapid Development of Unclassified Myeloid Lineage Acute Leukaemia With Trisomy 6 and U2AF1 Mutation. - Journal of Cellular and Molecular Medicine, 2025, Vol. 29, iss. 5
• [współaut.] Sośnia O, Iskierka-Jażdżewska E, Puła A [et al.] Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group. - Contemporary Oncology, 2025, T. 29, iss. 1, s. 28-35
• [współaut.] Stelljes M, Sockel K, Floeth M [et al.] Real world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS compared to clinical trial data. - Bone Marrow Transplantation, 2025, Vol. 60, iss. 1, p. 103-106
• [współaut.] Suska A, Tyczyńska A, Zaucha J [et al.] The Role of Lifestyle and Environmental Factors in the Pathogenesis of Multiple Myeloma. - European Journal of Haematology, 2025, Vol. 114, iss. 5, p. 812-821
• [współaut.] Beelen D, Iacobelli S, Koster L [et al.] Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison. - Bone Marrow Transplantation, 2024, Vol. 59, iss. 5, p. 670-679
• [współaut.] Clavero E, Sanchez-Maldonado J, Macauda A [et al.] Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma : A Meta-Analysis of Three Large Cohorts and Functional Characterization. - International Journal of Molecular Sciences, 2023, Vol. 24, iss. 10
• [współaut.] Beelen D, Stelljes M, Reményi P [et al.] Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients : Final analysis of a prospective randomized trial. - American Journal of Hematology, 2022, Vol. 97, iss. 8, p. 1023-1034
• [współaut.] Karaś A, Kawałko K, Płaczek A [et al.] Bosutynib w przewlekłej białaczce szpikowej u pacjentów z chorobami współistniejącymi. - Świat Medycyny i Farmacji, 2022, nr 5, s. 30-38
• [współaut.] Kawalec P, Holko P, Bungey G [et al.] Treosulfan-based conditioning vs. low-dose busulfan-based conditioning for allogeneic hematopoietic stem cell transplantation : a cost-utility analysis in Poland. - Acta Haematologica Polonica, 2022, Vol. 53, iss. 3, p. 191-200
• [współaut.] Rybicka-Ramos M, Suszka-Świtek A, Wiaderkiewicz R [et al.] Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation. - World Journal of Biological Chemistry, 2022, Vol. 13, iss. 4, p. 72-82
• [współaut.] Stölzel F, Stelljes M, Beelen D [et al.] GVHD and GFRS in patients with AML undergoing allogeneic transplantation with treosulfan- versus busulfan-based conditioning : a subgroup analysis of the randomized phase III MC-FludT.14/L trial. - Bone Marrow Transplantation, 2022, Vol. 57, iss. S1, p. 35-36
• [współaut.] Stelljes M, Trenschel R, Beelen D [et al.] Graft-versus-host disease (GVHD) and GVHD-free/relapse-free survival (GRFS) in patients with myelodysplastic syndrome (MDS) after treosulfan- versus busulfan-based conditioning and allogeneic hematopoietic cell transplantation (alloHCT). - Bone Marrow Transplantation, 2022, Vol. 57, iss. S1, p. 37
• [współaut.] Giaccherini M, Macauda A, Orciuolo E [et al.] Genetically determined telomere length and multiple myeloma risk and outcome. - Blood Cancer Journal, 2021, Vol. 11, iss. 4
• [współaut.] Macauda A, Piredda C, Clay-Gilmour A [et al.] Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. - International Journal of Cancer, 2021, Vol. 149, iss. 2, p. 327-336
• [współaut.] Opalińska A, Kwiatkowska D, Burdacki A [et al.] Multifocal Pyoderma Gangrenosum with an Underlying Hemophagocytic Lymphohistiocytosis : Case Report and the Review of the Literature. - Dermatology and Therapy, 2021, Vol. 11, iss. 4, p. 1217-1237
• [współaut.] Orlewska K, Bogusz K, Podlecka-Piętowska A [et al.] Impact of Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) on Treatment Cost of Multiple Sclerosis : Real-World Nationwide Study. - Value in Health Regional Issues, 2021, Vol. 25, p. 104-107
• [współaut.] Rybicka-Ramos M, Suszka-Świtek A, Wiaderkiewicz R [et al.] Proinflammatory cytokines as potential risk factors of acute graft-versus-host disease and infectious complications after allogeneic hematopoietic stem cell transplantation. - American Journal of Blood Research, 2021, Vol. 11, iss. 2, p. 149-156
• Allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria in the era of complement inhibition. - Acta Haematologica Polonica, 2021, Vol. 52, iss. 4, p. 253-256
• [współaut.] Beelen D, Trenschel R, Stelljes M [et al.] Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L) : a randomised, non-inferiority, phase 3 trial. - Lancet Haematology, 2020, Vol. 7, Iss. 1, p. E28-E39
• [współaut.] Drozd-Sokołowska J, Biecek P, Dzierzak-Mietla M [et al.] Allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria - multicenter analysis by Polish Adult Leukemia Group. - Biology of Blood and Marrow Transplantation, 2020, Vol. 26, iss. 10, p. 1833-1839
• [współaut.] Dzierżak-Mietła M, Gaj M, Warzybok K [et al.] Similar effectiveness of Fomukal and Caphosol in oral mucositis treatment after allogeneic hematopoietic stem cell transplantati. - Postępy Higieny i Medycyny Doświadczalnej, 2020, Vol. 74, s. 541-547
• Charakterystyka wykorzystania oksykodonu w leczeniu bólu nowotworowego i pozanowotworowego w specjalistycznej praktyce lekarskiej w Polsce : wyniki wieloośrodkowego badania obserwacyjnego. Warszawa, Accord Healthcare Polska Sp. Z o.o.: 2020, 7 s.
• [współaut.] Canaani J, Beohou E, Labopin M [et al.] Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis. - Journal of Internal Medicine, 2019, Vol. 285, iss. 4, s. 407-418
• [współaut.] Helbig G, Chromik K, Woźniczka K [et al.] Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia. - Pathology and Oncology Research, 2019, Vol. 25, iss. 3, s. 1175-1180
• [współaut.] Helbig G, Spałek A, Wieczorkiewicz-Kabut A [et al.] Allogeneic transplantation for high-risk chronic lymphocytic leukemia - a summary of a 16-year experience. - Annals of Hematology, 2019, Vol. 98, iss. 6, p. 1477-1483
• [współaut.] Helbig G, Wieczorkiewicz-Kabut A, Krzemień H [et al.] Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis. - Medical Oncology, 2019, Vol. 36, iss. 2, art. no. 16
• [współaut.] Miano M, Eikema D, Aljurf M [et al.] Stem cell transplantation for congenital dyserythropoietic anemia : An analysis from the european society for blood and marrow transplantation. - Haematologica, 2019, Vol. 104, iss. 8, p. E335-E339